Elyxyb - Celecoxib

The dosage of celecoxib is highly individualized based on the condition being treated and the patient's overall health profile. Healthcare providers generally aim for the lowest effective dose for the shortest duration possible to minimize cardiovascular and gastrointestinal risks.

• Osteoarthritis: The standard dose is 200 mg per day. This can be taken as a single 200 mg dose or divided into two 100 mg doses (one in the morning and one in the evening).
• Rheumatoid Arthritis: The typical range is 100 mg to 200 mg taken twice daily (totaling 200 mg to 400 mg per day).
• Ankylosing Spondylitis: The starting dose is usually 200 mg per day (either once daily or 100 mg twice daily). If no improvement is seen after six weeks, your doctor may increase the dose to 400 mg per day.
• Acute Pain and Menstrual Cramps: The recommended starting dose is 400 mg as a single dose, followed by an additional 200 mg on the first day if needed. On subsequent days, the dose is typically 200 mg twice daily as required.

Celecoxib is approved for Juvenile Rheumatoid Arthritis (JRA) in children aged 2 years and older. Dosing is strictly weight-based:

• Children 10 kg to 25 kg: 50 mg taken twice daily.
• Children more than 25 kg: 100 mg taken twice daily.

Safety and efficacy have not been established in children weighing less than 10 kg or those younger than 2 years of age.

Renal Impairment

Celecoxib is not recommended for patients with advanced renal (kidney) disease. In patients with mild to moderate renal impairment, close monitoring is required as NSAIDs can further reduce kidney blood flow. If a patient develops worsening kidney function, the medication should be discontinued.

Hepatic Impairment

For patients with moderate hepatic (liver) impairment (Child-Pugh Class B), the daily dose of celecoxib should be reduced by approximately 50%. Celecoxib is not recommended for patients with severe hepatic impairment (Child-Pugh Class C).

Elderly Patients

While no specific dose adjustment is generally required for elderly patients, they are at a significantly higher risk for serious GI and renal side effects. Healthcare providers often start elderly patients at the lowest end of the dosing range and monitor them closely for signs of internal bleeding or fluid retention.

• Consistency: Celecoxib can be taken with or without food. However, taking it with a meal may help reduce the chance of stomach upset.
• Swallowing: Capsules should be swallowed whole with a full glass of water. For patients who cannot swallow capsules, the contents of a celecoxib capsule can be emptied onto a level teaspoon of cool or room-temperature applesauce and swallowed immediately with water.
• Timing: If taking twice daily, try to space the doses roughly 12 hours apart to maintain consistent blood levels.
• Storage: Store at room temperature (68°F to 77°F or 20°C to 25°C), away from moisture, heat, and direct sunlight.

If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of side effects.

Symptoms of a celecoxib overdose may include lethargy (extreme tiredness), drowsiness, nausea, vomiting, and epigastric pain (pain in the upper abdomen). In severe cases, gastrointestinal bleeding, high blood pressure, acute kidney failure, respiratory depression, and coma can occur.

In the event of a suspected overdose, seek emergency medical attention or contact a poison control center immediately. Treatment is typically supportive and symptomatic; there is no specific antidote for celecoxib. Because the drug is highly protein-bound, hemodialysis is unlikely to be effective in removing it from the bloodstream.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this could lead to a return of inflammatory symptoms or increased risk of complications.

While celecoxib is generally well-tolerated, some patients experience mild to moderate side effects. The most frequently reported include:

• Gastrointestinal Upset: This includes dyspepsia (indigestion), heartburn, and mild stomach pain. These symptoms often occur shortly after taking the medication and may improve if the drug is taken with food.
• Diarrhea or Constipation: Changes in bowel habits are common as the body adjusts to the medication.
• Upper Respiratory Tract Infections: Some patients report symptoms similar to a common cold, including a sore throat or runny nose.
• Peripheral Edema: Mild swelling of the hands, ankles, or feet due to fluid retention.

• Dizziness and Headache: Some individuals may feel lightheaded or experience tension-type headaches.
• Insomnia: Difficulty falling or staying asleep has been reported in a small percentage of users.
• Pharyngitis and Rhinitis: Inflammation of the throat and nasal passages.
• Skin Rash: Mild itching or redness of the skin.
• Flatulence: Increased gas and abdominal bloating.

• Tinnitus: Ringing in the ears.
• Blurred Vision: Temporary changes in visual acuity.
• Anemia: A decrease in red blood cell count, often due to occult (hidden) GI bleeding.
• Hyperkalemia: Elevated levels of potassium in the blood, which can affect heart rhythm.

> Warning: Stop taking Celecoxib and call your doctor immediately if you experience any of the following serious symptoms:

• Cardiovascular Events: Chest pain, shortness of breath, weakness on one side of the body, or slurred speech. These may be signs of a heart attack or stroke.
• Gastrointestinal Bleeding: Black, tarry, or bloody stools; coughing up blood or vomit that looks like coffee grounds. This is a medical emergency.
• Hepatotoxicity (Liver Damage): Yellowing of the skin or eyes (jaundice), dark urine, severe fatigue, or pain in the upper right side of the stomach.
• Nephrotoxicity (Kidney Damage): Significant change in the amount of urine produced, swelling in the legs, or shortness of breath.
• Severe Skin Reactions: Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). Watch for a painful red or purplish rash that spreads and blisters, accompanied by fever.
• Anaphylaxis: Severe allergic reaction involving swelling of the face or throat, hives, and difficulty breathing.

Prolonged use of celecoxib, especially at high doses, increases the cumulative risk of cardiovascular and renal issues. Chronic inhibition of prostaglandins in the kidneys can lead to renal papillary necrosis (death of kidney tissue) and other forms of chronic kidney disease. Long-term users should have regular blood pressure checks and lab work to monitor organ function.

The FDA has issued the highest level of warning for celecoxib, known as a Black Box Warning, regarding two major risks:

1. 1Cardiovascular Risk: NSAIDs, including celecoxib, cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Celecoxib is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
2. 2Gastrointestinal Risk: NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

Report any unusual symptoms, no matter how minor they may seem, to your healthcare provider immediately. Early detection of side effects is key to preventing long-term complications.

Celecoxib is a powerful medication that requires careful screening by a healthcare professional. It is not suitable for everyone, particularly those with pre-existing heart or stomach conditions. Patients must be aware that even if they have tolerated other NSAIDs like ibuprofen in the past, celecoxib has a unique pharmacological profile that requires specific precautions.

As mandated by the FDA, celecoxib carries prominent warnings regarding cardiovascular and gastrointestinal safety.

• Cardiovascular Thrombotic Events: Clinical trials have shown that COX-2 selective and non-selective NSAIDs increase the risk of heart attack and stroke. This risk is present in patients with and without heart disease or risk factors for heart disease. However, those with a history of heart disease face the highest absolute risk.
• Gastrointestinal Bleeding, Ulceration, and Perforation: Celecoxib can cause damage to the stomach and intestinal lining. This risk is significantly higher in patients who take corticosteroids (like prednisone), anticoagulants (blood thinners), or those who smoke or consume alcohol regularly.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known 'aspirin triad' (asthma, nasal polyps, and aspirin sensitivity) should not take celecoxib. Severe, life-threatening bronchial spasms can occur. Additionally, because celecoxib contains a sulfonamide moiety, patients with a history of sulfa allergies may be at higher risk for allergic reactions.
• Hepatotoxicity: Borderline elevations of liver tests may occur in up to 15% of patients. While rare, severe hepatic reactions including liver failure and jaundice have been reported. If symptoms of liver dysfunction develop, the drug must be stopped immediately.
• Hypertension (High Blood Pressure): Celecoxib can lead to the onset of new hypertension or the worsening of pre-existing high blood pressure. Blood pressure should be monitored closely during the initiation of therapy and throughout the course of treatment.
• Heart Failure and Edema: NSAIDs can cause fluid retention and edema (swelling). Celecoxib should be used with extreme caution in patients with congestive heart failure or pre-existing swelling.
• Renal Toxicity: Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Patients at greatest risk are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly.

If you are prescribed celecoxib for a chronic condition, your healthcare provider will likely require periodic monitoring, including:

• Complete Blood Count (CBC): To check for anemia, which could indicate internal bleeding.
• Liver Function Tests (LFTs): To ensure the liver is processing the medication safely.
• Renal Function Tests (BUN and Creatinine): To monitor kidney health.
• Blood Pressure: Regular checks are necessary as NSAIDs can raise blood pressure levels.

Celecoxib generally does not cause significant sedation. However, because it can cause dizziness or blurred vision in some individuals, you should observe how the medication affects you before driving or operating heavy machinery.

Consuming alcohol while taking celecoxib significantly increases the risk of gastrointestinal bleeding and stomach ulcers. It is generally advised to limit or avoid alcohol consumption during treatment.

Unlike some medications, celecoxib does not typically require a tapering schedule to avoid withdrawal. However, stopping the medication may result in a rapid return of inflammatory symptoms (pain and swelling). Always consult your doctor before discontinuing a prescribed regimen for chronic arthritis.

> Important: Discuss all your medical conditions, especially any history of heart disease, high blood pressure, or stomach ulcers, with your healthcare provider before starting Celecoxib.

While few drugs are strictly 'contraindicated' in the absolute sense, certain combinations are so dangerous they should be avoided unless under extreme specialist supervision:

• Other NSAIDs (e.g., Naproxen, Ibuprofen, Ketorolac): Taking celecoxib with other NSAIDs does not increase efficacy but significantly multiplies the risk of gastrointestinal bleeding and kidney damage.
• Cidofovir: Combining NSAIDs with this antiviral can lead to severe kidney toxicity.

• Warfarin and Anticoagulants: Celecoxib can increase the risk of bleeding complications, particularly in the gastrointestinal tract. Furthermore, NSAIDs can interfere with platelet function. Patients on warfarin (Coumadin) must have their INR (International Normalized Ratio) monitored very closely when starting or changing celecoxib doses.
• Lithium: Celecoxib can decrease the renal clearance of lithium, leading to toxic levels of lithium in the blood. Symptoms of lithium toxicity include tremors, confusion, and muscle weakness.
• Methotrexate: NSAIDs can reduce the excretion of methotrexate, potentially leading to bone marrow suppression or kidney toxicity.
• ACE Inhibitors, ARBs, and Beta-Blockers: Celecoxib may diminish the blood-pressure-lowering effects of these medications. Additionally, the combination of an ACE inhibitor and an NSAID in elderly or dehydrated patients can lead to acute kidney failure.
• Fluconazole: This antifungal inhibits the CYP2C9 enzyme, which breaks down celecoxib. Taking them together can double the concentration of celecoxib in the blood. Healthcare providers typically recommend using the lowest dose of celecoxib in these patients.

• Diuretics (e.g., Furosemide, Hydrochlorothiazide): Celecoxib can reduce the natriuretic (sodium-removing) effect of diuretics, leading to fluid retention and decreased effectiveness in treating high blood pressure or edema.
• Digoxin: Some NSAIDs can increase serum digoxin levels; monitoring is advised.
• Corticosteroids: Taking celecoxib with prednisone or other steroids significantly increases the risk of developing stomach ulcers.

• High-Fat Meals: As noted in the pharmacology section, high-fat food increases the total absorption of celecoxib. While the drug can be taken with or without food, it is best to be consistent. If you take it with breakfast every day, continue to do so.
• Alcohol: Increases the risk of GI irritation and bleeding. Avoidance is strongly recommended.

• Ginkgo Biloba, Garlic, and Ginger: These supplements have mild anti-platelet effects and may increase the risk of bleeding when combined with celecoxib.
• St. John’s Wort: This herb can induce CYP enzymes, potentially reducing the effectiveness of celecoxib, though the clinical significance is less clear than with other drugs.
• Omega-3 Fatty Acids: While often taken for arthritis, high doses may increase bleeding risk when used with NSAIDs.

Celecoxib does not generally interfere with standard laboratory tests, but it may cause false-positive results in certain urine tests for other substances. It can also cause elevations in liver enzymes and BUN/creatinine, which are reflections of the drug's physiological effects rather than an interference with the test mechanism itself.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is essential for preventing dangerous drug-drug interactions.

Celecoxib must NEVER be used in the following circumstances:

• Hypersensitivity: Known allergy to celecoxib or any component of the capsule formulation.
• Sulfonamide Allergy: Celecoxib contains a sulfonamide group. Patients who have demonstrated allergic-type reactions to sulfonamides (e.g., 'sulfa' drugs like Bactrim) may experience cross-reactivity, including skin rashes or anaphylaxis.
• Aspirin-Sensitive Asthma: Patients who have experienced asthma, hives, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic-like reactions have occurred in such patients.
• CABG Surgery: Celecoxib is strictly contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery due to an increased risk of heart attack and stroke in the immediate post-operative period.

These conditions require a careful risk-benefit analysis by a physician:

• Active Peptic Ulcer Disease: Patients with active stomach or intestinal bleeding should not start celecoxib until the condition is resolved.
• Severe Heart Failure: Due to the risk of fluid retention and worsening cardiac function.
• Severe Renal Impairment: Patients with a creatinine clearance of less than 30 mL/min should generally avoid celecoxib.
• Severe Hepatic Impairment: (Child-Pugh Class C) The drug is not recommended as the liver cannot process it effectively.
• Late Pregnancy: Use is contraindicated starting at 30 weeks of gestation due to the risk of premature closure of the ductus arteriosus in the fetus.

Patients should be aware of cross-sensitivity between celecoxib and other NSAIDs. If you have had a severe reaction to ibuprofen, naproxen, diclofenac, or indomethacin, you are likely to have a similar reaction to celecoxib. Furthermore, the sulfonamide cross-reactivity is a unique consideration for this specific drug compared to other NSAIDs.

> Important: Your healthcare provider will evaluate your complete medical history, including all past allergic reactions, before prescribing Celecoxib. Do not assume that because it is a 'selective' inhibitor, it is safe for those with NSAID allergies.

• First and Second Trimester: Celecoxib is generally classified as Category C (prior to 30 weeks). It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Some studies suggest that the use of NSAIDs in early pregnancy may increase the risk of miscarriage.
• Third Trimester (30 weeks and beyond): Celecoxib is contraindicated (Category D). NSAIDs can cause premature closure of the fetal ductus arteriosus (a vital blood vessel in the fetal heart) and can lead to fetal renal dysfunction, resulting in low amniotic fluid (oligohydramnios).
• Fertility: Like other drugs that inhibit cyclooxygenase and prostaglandin synthesis, celecoxib may delay or prevent ovulation. This is reversible upon discontinuation of the drug.

Data from limited studies indicate that celecoxib passes into human breast milk in very small amounts. The levels found in milk are much lower than those required for therapeutic effect in an infant. However, because of the potential for serious adverse reactions in nursing infants from celecoxib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Celecoxib is approved for the treatment of Juvenile Rheumatoid Arthritis (JRA) in children aged 2 to 17 years. It has not been studied in children under the age of 2 or those weighing less than 10 kg. Long-term effects on growth and development have not been specifically documented, but pediatric patients should be monitored with the same rigor as adults, particularly for renal and GI effects.

Patients over the age of 65 are at a substantially higher risk for complications from celecoxib. Of the total number of patients in clinical studies of celecoxib, a significant portion were 65 and over. While no overall differences in effectiveness were observed between these subjects and younger subjects, fatal GI events and acute renal failure are more common in the elderly. Lower starting doses and frequent monitoring are standard of care for this population.

In patients with mild to moderate renal impairment, no specific dose adjustment is typically required, but extreme caution is necessary. Celecoxib is not recommended in patients with advanced renal disease. If treatment must be initiated in a patient with kidney disease, renal function must be monitored frequently.

• Mild (Child-Pugh Class A): No dose adjustment is usually necessary.
• Moderate (Child-Pugh Class B): The daily dose should be reduced by 50%.
• Severe (Child-Pugh Class C): Use is not recommended.

> Important: Special populations require individualized medical assessment. Dosage and safety monitoring must be tailored to the specific needs of these vulnerable groups.

Celecoxib is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic, and antipyretic (fever-reducing) activities. The mechanism of action is primarily through the inhibition of prostaglandin synthesis via the selective inhibition of cyclooxygenase-2 (COX-2). At therapeutic concentrations in humans, celecoxib does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. COX-2 is induced in settings of inflammation; its inhibition leads to a reduction in the synthesis of prostaglandins (specifically PGE2), which are the primary mediators of pain, swelling, and inflammation.

• Dose-Response: There is a clear dose-response relationship for pain relief, though the curve flattens at higher doses (e.g., 400 mg vs 800 mg for certain conditions).
• Time to Onset: For acute pain, onset occurs within 30 to 60 minutes. For chronic arthritis, the full anti-inflammatory effect may take 1 to 2 weeks of consistent dosing.
• Platelet Function: Unlike non-selective NSAIDs, celecoxib at therapeutic doses does not affect platelet aggregation or bleeding time because it does not inhibit COX-1 in platelets.

| Parameter | Value |

|---|---|

| Bioavailability | ~90% (relative to suspension) |

| Protein Binding | 97% |

| Half-life | 11 hours |

| Tmax | 3 hours |

| Metabolism | Hepatic (Primarily CYP2C9) |

| Excretion | Fecal 57%, Renal 27% |

• Molecular Formula: C17H14F3N3O2S
• Molecular Weight: 381.37 g/mol
• Solubility: Celecoxib is highly hydrophobic (water-fearing) and is essentially insoluble in water at physiological pH.
• Structure: It is a diaryl-substituted pyrazole. The presence of the sulfonamide group is a key structural feature that differentiates it from other NSAIDs and contributes to its COX-2 selectivity.

Celecoxib is the primary representative of the 'Coxib' class of NSAIDs. It is therapeutically categorized as an anti-rheumatic and analgesic agent. Related medications historically included rofecoxib (Vioxx) and valdecoxib (Bextra), though celecoxib is currently the only selective COX-2 inhibitor widely available in the United States and many other global markets.